Robbie Woodman
Voorzitter bij Transine Therapeutics Ltd.
Profiel
At Panakes since 2021, Dr. Rob Woodman has global experience in biotech gained in both institutional and corporate venture firms, encompassing de novo start-up through to growth investments, with a track record of value creation in all of these settings as demonstrated by multiple acquisitions and NASDAQ listings of the companies he has invested in.
Previously, Rob was Senior Partner at Takeda Ventures, where he helped build the team and portfolio, sat on the boards of a number of companies including Emendo Bio (acquired by Anges Pharma) and BioMx Inc (NASDAQ: PHGE), and was also the Head of Genesis Labs, Takeda's internal concept incubator.
Prior to joining Takeda, Rob was Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London where he led the formation of and investment into a portfolio of UK biotech companies including Enterprise Therapeutics (potentiator programme acquired by Roche) and Inivata (acquired by Neogenomics).
Before this, Rob was a Principal in the life science team at Sofinnova Partners, a leading European venture capital firm.
Whilst at Sofinnova, he was actively involved in numerous investments throughout Europe and the US, including Ascendis Pharma (NASDAQ; ASND) Omthera Inc (acquired by AstraZeneca).
Education
PhD Oncology - University of Cambridge MSc Biochemistry - University of Oxford
Actieve functies van Robbie Woodman
| Bedrijven | Functie | Begin |
|---|---|---|
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Transine Therapeutics Ltd.
 Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Voorzitter | - |
Panakes Partners SGR SpA
 Panakes Partners SGR SpA Investment ManagersFinance Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy. | Private Equity Investor | 01-01-2021 |
Eerdere bekende functies van Robbie Woodman
| Bedrijven | Functie | Einde |
|---|---|---|
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01-09-2021 |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Corporate Officer/Principal | 01-09-2021 |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Corporate Officer/Principal | - |
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Private Equity Investor | - |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Corporate Officer/Principal | - |
Opleiding van Robbie Woodman
| University of Oxford | Graduate Degree |
| University of Cambridge | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOMX INC. | Health Technology |
| Bedrijven in privébezit | 9 |
|---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Finance |
Panakes Partners SGR SpA
Panakes Partners SGR SpA Investment ManagersFinance Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy. | Finance |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Health Technology |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Abintus Bio, Inc.
 Abintus Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA. | Commercial Services |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Health Technology |
